The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Christ I thought this board was disharmonious - nothing compared to that. Far too detailed for me - I wouldn't even pretend to understand the science behind Scancell or even the maths behind the ORR % calculations. Think I'll stick to this board!!
Hi all
Been reading this message board and watching the falling share price over the last few months. Having bought in at a lower price initially and topped up at a higher price, I find myself at more or less break even (shame I didn't sell at a good profit in the mid 20p's but hey ho!)
Been thinking about topping up but so often when I do a dummy purchase I notice the price has edged down a little more! It feels like trying to catch a very sharp falling knife! There will be a bottom just don't know where it is - lets face it, if we could predict that we'd all be millionaires!
I remain optimistic for Scancell and the trials and confident that we will (eventually!) hear positive news and see a material uplift in the share price. My own personal view is to hold what I have - if it goes down to 8p over the next few weeks I will top up. If the SP takes off and I miss out then so be it - I'll still be in profit.
Sorry for the ramblings - think it helps putting it in black and white rather than swirling around in my head!
Yes my thoughts exactly violindog.
I'm applying for some excess shares, no doubt it will get scaled back but will then reassess before the new year with a view to maybe topping up in the open market.
Cheers
Morning all - looking for a bit of clarification / understanding.
First of all, I think the open offer is looking to raise gross £8m? Is that figure (or whatever the figure is) based on everyone taking up the option of buying one share for every 45 they have or does it rely on PI buying excess shares as well? (I appreciate that overseas investors cannot partake in the offer.)
I'm with Jarvis who for some reason only got notification of this on Friday and I now have the letter inviting participation in the OO (instructions must be with them by tomorrow so sorting this out today.)
Looking at buying in the open market today there is a big difference in the bid / offer. I can buy at 11.25 which guarantees I'll get what I want but at slightly above the OO price. Interestingly, to sell it would be 10.75 - the MM know what they're doing!!!
Anyway, my thinking is that irrespective of the small difference in price, it would be better to buy in the OO as that cash would go into Scancells coffers rather than a slice going in the back pocket of the MM. I guess the gamble is that in the event of being oversubscribed, I wouldn't get as many as I'd asked for. If the OO was oversubscribed, I wonder if they would increase the allocation like they did in the placing to raise additional funds?
Would welcome thoughts.....................
I'm feeling a bit underwhelmed by this RNS. Of course its great that Cohort1 has seen no adverse side effects but am I right in thinking that after several months Scancell have only recruited 3 patients? Someone please tell me I have got this wrong!
If I haven't we may be waiting a long time until Cohort 2 is fully recruited and even further for efficacy data.
AB "So we're looking at an inexperienced CEO helping a potentially multimillion company who's also CSO of that company whilst also holding down a position at a uk university"
LD's primary expertise is in the science and she may be the CEO but I don't imagine she will be sat around a table with Biotech companies on her own! She will have a team around her all experts in their field who will advise her and of course the BoD, there will be professional advisers too.
As you say - horses for courses. Keep the faith and this is not just blind optimism.